New personalized combo could let some stomach cancer patients skip surgery
NCT ID NCT07290985
First seen Jan 10, 2026 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study tests a personalized treatment plan for people with stomach or esophageal cancer. Doctors will use tumor markers to pick the best mix of chemotherapy, immunotherapy, and targeted drugs. The goal is to shrink the cancer enough that some patients may avoid surgery entirely. About 121 people will take part, and those who skip surgery will be closely watched with scans and scopes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.